RLIP76 expression as a prognostic marker of breast cancer

被引:0
|
作者
Wang, C. -Z. [1 ]
Yuan, P. [1 ]
Xu, B. [2 ]
Yuan, L. [3 ]
Yang, H. -Z. [1 ]
Liu, X. [4 ]
机构
[1] Zhengzhou Univ, Affiliated Canc Hosp, Breast Canc Ctr, Zhengzhou 450052, Henan, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Cent Lab, Zhengzhou 450052, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Dept Surg, Zhengzhou 450052, Henan, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Dept Radiotherapy, Zhengzhou 450052, Henan, Peoples R China
关键词
RLIP76; Breast cancer; Prognosis; RAL-BINDING PROTEIN-1; DOXORUBICIN RESISTANCE; LUNG-CANCER; INCREASES CHEMOSENSITIVITY; INHIBITS PROLIFERATION; DEPENDENT TRANSPORT; ENHANCES APOPTOSIS; TUMOR-TISSUE; EFFECTOR; IDENTIFICATION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: RLIP (Ral-interacting protein)-76/RalBP11 (Ral-binding protein-1), a multifunctional protein and stress-inducible non-ABC transporter, have been proven to serve as a critical role in cancer development and progression; however, little is known about the pathological role of RLIP76 in breast cancer patients. The study aimed to determine the correlation between RLIP76 expression in breast cancer patient and clinical outcomes. PATIENTS AND METHODS: Using RT-PCR and Western blot, messenger RNA (mRNA) and protein expression of RLIP76 were determined in breast cancer and adjacent normal mammary tissues. The relationship of RLIP76 expression with clinical characteristics of 245 breast cancer patients was analyzed by immunohistochemistry. RESULTS: In the present study, our results indicated that RLIP76 mRNA and protein were highly expressed in the breast cancer tissues while compared with adjacent normal mammary tissues and the correlation with RLIP76 protein expression was significantly associated with age (the non-ABC transporter, stage and the expression were significantly associated-T2 vs. T3-T4, p < 0.01), lymph node metastasis (N0-N1 vs. N2-N3, p < 0.01), and PR (positive vs. negative, p < 0.01) in breast cancer patients; furthermore, we also found that RLIP76 protein overexpression was an unfavorable prognostic factor in the patients suffered from breast cancer. CONCLUSIONS: RLIP76 overexpression serves as an unfavorable prognostic biomarker in breast cancer patients.
引用
收藏
页码:2105 / 2111
页数:7
相关论文
共 50 条
  • [1] RLIP76 and cancer
    Awasthi, Sanjay
    Singhal, Sharad S.
    Awasthi, Yogesh C.
    Martin, Bryan
    Woo, Jung-Hee
    Cunningham, C. Casey
    Frankel, Arthur E.
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4372 - 4377
  • [2] RLIP76 EXPRESSION IS PROGNOSTIC AND PREDICTIVE OF CHEMOTHERAPY BENEFIT IN RESECTED NSCLC
    Urban, Damien
    Young, Richard J.
    Wainer, Zoe
    Conron, Matthew
    Russell, Prudence A.
    Wright, Gavin
    Solomon, Ben
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1071 - S1072
  • [3] THE EXPRESSION OF RLIP76 AND MRP IN LEUKEMIA CELLS
    Toylu, A.
    Clark, O. Altiok
    Salim, O.
    Timuragaoglu, A. Irfanoglu
    HAEMATOLOGICA, 2012, 97 : 552 - 552
  • [4] RLIP76: A Target for Kidney Cancer Therapy
    Singhal, Sharad S.
    Singhal, Jyotsana
    Yadav, Sushma
    Sahu, Mukesh
    Awasthi, Yogesh C.
    Awasthi, Sanjay
    CANCER RESEARCH, 2009, 69 (10) : 4244 - 4251
  • [5] RLIP76 Targeted Therapy for Kidney Cancer
    Sharad S. Singhal
    Jyotsana Singhal
    James Figarola
    David Horne
    Sanjay Awasthi
    Pharmaceutical Research, 2015, 32 : 3123 - 3136
  • [6] RLIP76 Targeted Therapy for Kidney Cancer
    Singhal, Sharad S.
    Singhal, Jyotsana
    Figarola, James
    Horne, David
    Awasthi, Sanjay
    PHARMACEUTICAL RESEARCH, 2015, 32 (10) : 3123 - 3136
  • [7] Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76
    Awasthi, S
    Singhal, SS
    Singhal, J
    Cheng, JH
    Zimniak, P
    Awasthi, YC
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 22 (04) : 713 - 720
  • [8] RLIP76: A Target for Kidney Cancer Therapy
    Singhal, Sharad S.
    Yadav, Sushma
    Singhal, Jyotsana
    Awasthi, Yogesh C.
    Awasthi, Sanjay
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 931 - 931
  • [9] Targeting kidney cancer through RLIP76
    Singhal, Sharad
    Yadav, Sushma
    Singhal, Jyotsana
    Awasthi, Yogesh
    Awasthi, Sanjay
    CANCER RESEARCH, 2009, 69
  • [10] Regression of prostate cancer xenografts by RLIP76 depletion
    Singhal, Sharad S.
    Roth, Cherice
    Leake, Kathryn
    Singhal, Jyotsana
    Yadav, Sushma
    Awasthi, Sanjay
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (06) : 1074 - 1083